Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ACRV
Stock Latest News
Company Announcements
Acrivon Highlights Positive ACR-368 Data and 2025 Results
1M ago
8K
ACRV
Premium
The Fly
Acrivon plans to initiate fourth cohort in ACR-368 Phase 2b study
1M ago
ACRV
Premium
The Fly
Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)
1M ago
ACRV
Premium
The Fly
Acrivon Therapeutics sees cash runway into 2Q27
1M ago
ACRV
Premium
Ratings
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon
2M ago
ACRV
Premium
Company Announcements
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
2M ago
8K
ACRV
Premium
The Fly
Acrivon Therapeutics announces completion, certification of CLIA certified lab
2M ago
ACRV
Premium
Market News
3 Best Stocks to Buy Today, 1/22/2026, According to Top Analysts
3M ago
ACRV
META
Premium
The Fly
Acrivon Therapeutics price target raised to $8 from $6 at Piper Sandler
3M ago
ACRV
Premium
Ratings
Balancing Early Promise and Significant Uncertainty: Maintaining a Hold on Acrivon Therapeutics Amid Limited Data and Long-Dated Clinical Risk
3M ago
ACRV
Premium
Ratings
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating
3M ago
ACRV
Premium
Market News
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
3M ago
F
AEP
Premium
Company Announcements
Acrivon Showcases Promising Phase 2b Oncology Data Update
3M ago
8K
ACRV
Premium
Market News
Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results
3M ago
ACRV
Premium
Company Announcements
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
3M ago
8K
ACRV
Premium
The Fly
Acrivon Therapeutics announces progress across pipeline
3M ago
ACRV
Premium
The Fly
Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies
3M ago
ACRV
Premium
The Fly
Acrivon to provide ACR-368, ACR-2316 clinical data in January
4M ago
ACRV
Premium
Ratings
Optimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments
5M ago
ACRV
Premium
Market News
3 Best Stocks to Buy Now, 11/14/2025, According to Top Analysts
5M ago
ACRV
DASH
Premium
Ratings
Positive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements
5M ago
ACRV
Premium
Company Announcements
Acrivon Therapeutics Reports Q3 2025 Financial Results
5M ago
ACRV
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
